Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,494,944
  • Shares Outstanding, K 2,724,440
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.76
  • Price/Sales 3.80
  • Price/Cash Flow 9.59
  • Price/Book 3.95

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.63 +5.91%
on 11/20/17
56.80 unch
on 12/12/17
+1.32 (+2.38%)
since 11/10/17
3-Month
53.63 +5.91%
on 11/20/17
66.41 -14.47%
on 09/18/17
-8.66 (-13.23%)
since 09/12/17
52-Week
53.63 +5.91%
on 11/20/17
66.80 -14.97%
on 03/01/17
-4.92 (-7.97%)
since 12/12/16

Most Recent Stories

More News
Poultry Health Market Value to Reach US$11.0 Billion by the End of 2025: Transparency Market Research

Transparency Market Research observes that global poultry health market is highly fragmented due to strong presence of several players. The consistent entry of new players in the market is making the competitive...

MRK : 56.75 (+0.73%)
ZTS : 71.77 (-0.15%)
Diabetes Drugs Market Value to Reach US$58.4 billion by the End of 2025: Transparency Market Research

Transparency Market Research observes that the global diabetes drugs market is likely to witness intense competition in the coming years due to a strong presence of several vendors. Companies operating...

BAYRY : 31.1090 (+0.81%)
NVO : 52.70 (+0.53%)
MRK : 56.75 (+0.73%)
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018

Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.

JNJ : 141.45 (+0.22%)
MRK : 56.75 (+0.73%)
VRTX : 139.66 (-1.43%)
BMRN : 88.11 (+7.46%)
INCY : 97.25 (+0.69%)
PFE : 36.25 (+0.11%)
ALXN : 111.90 (-2.24%)
Merck Signs Distribution Agreement with Avanti® Polar Lipids

- Merck to distribute top lipid portfolio outside of United States

MRK : 56.75 (+0.73%)
FDA Accepts Supplemental Biologics License Application (sBLA), Assigns Priority Review to Merck's KEYTRUDA(R) (pembrolizumab) for Treatment of Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

--Findings from KEYNOTE-170 Presented at 59th American Society of Hematology (ASH) Annual Meeting

MRK : 56.75 (+0.73%)
New Highs for S&P, Dow on Strong Jobs Report

New Highs for S&P, Dow on Strong Jobs Report

PAYX : 69.02 (+0.01%)
MRK : 56.75 (+0.73%)
Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS

HATFIELD, England, December 8, 2017 /PRNewswire/ --

MRK : 56.75 (+0.73%)
Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS

Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in combination with the Merck & Co., Inc., Kenilworth, NJ,...

MRK : 56.75 (+0.73%)
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen

MRK : 56.75 (+0.73%)
ESALF : 55.1500 (-0.18%)
Neon Therapeutics Announces Clinical Trial Collaboration with Merck

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has entered a clinical trial collaboration with Merck (known...

MRK : 56.75 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 57.25
1st Resistance Point 56.79
Last Price 56.80
1st Support Level 55.72
2nd Support Level 55.11

See More

52-Week High 66.80
Fibonacci 61.8% 61.77
Fibonacci 50% 60.22
Fibonacci 38.2% 58.66
Last Price 56.80
52-Week Low 53.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.